Patents by Inventor DANNY CARRERO

DANNY CARRERO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents
    Patent number: 9895446
    Abstract: Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness. The disclosed poloxamer-based intralesional injections are employed for treating different types of cancer in humans and other animal species. The disclosed intralesional injections can be used as the sole therapy or in combination with one or more additional therapies, such as, chemotherapy, electrotherapy, immunotherapy and/or radiation therapy. The disclosed intralesional injections can be employed in virotherapy and gene therapy treatments. The disclosed intralesional injections are designed for immediate release or controlled release of the active drugs. The disclosed intralesional injections are employed for local or systemic administration of active drugs.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 20, 2018
    Assignees: Professional Compounding Centers of America, Best Pet Rx IP, Inc.
    Inventors: Chris V. Simmons, Danny Carrero
  • POLOXAMER-BASED INTRALESIONAL INJECTIONS FOR THE DELIVERY OF CHEMOTHERAPEUTIC AGENTS
    Publication number: 20170014514
    Abstract: Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness. The disclosed poloxamer-based intralesional injections are employed for treating different types of cancer in humans and other animal species. The disclosed intralesional injections can be used as the sole therapy or in combination with one or more additional therapies, such as, chemotherapy, electrotherapy, immunotherapy and/or radiation therapy. The disclosed intralesional injections can be employed in virotherapy and gene therapy treatments. The disclosed intralesional injections are designed for immediate release or controlled release of the active drugs. The disclosed intralesional injections are employed for local or systemic administration of active drugs.
    Type: Application
    Filed: July 14, 2016
    Publication date: January 19, 2017
    Inventors: CHRIS V. SIMMONS, DANNY CARRERO